Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas
Executive Summary
As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said
You may also be interested in...
Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
With the growing problem of antimicrobial resistance putting the spotlight on the need for novel antibiotics, FDA has opened the debate on whether incentives, similar to the orphan drug system, are needed to prompt R&D in the area. But at a recent workshop on the issue, advocacy groups suggested that any such incentives need to be partnered with a more active role on the part of FDA
Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
With the growing problem of antimicrobial resistance putting the spotlight on the need for novel antibiotics, FDA has opened the debate on whether incentives, similar to the orphan drug system, are needed to prompt R&D in the area. But at a recent workshop on the issue, advocacy groups suggested that any such incentives need to be partnered with a more active role on the part of FDA
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved